Search Results

Cochlear Limited (ASX: COH) obtained U.S. Food and Drug Administration (FDA) clearance to lower the age of the Cochlear™ Osia System from 12 years-old to 5-years-old for children with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness (SSD).

Sensorion announces that promising new data and analysis results from the SENS-401 following cochlear implantation Phase 2a clinical study will be presented at the 17th International Conference on Cochlear Implants and Other Implantable Technologies taking place on July 10-13, 2024, in Vancouver, Canada.

Sound Pharmaceuticals (SPI) is pleased to announce that it has received FDA notification that its Investigational New Drug Application (IND) may proceed involving SPI-1005 treatment and cochlear implantation (CI).

Sensorion announces the recruitment of the last patient in its Phase 2a clinical trial of SENS-401 for residual hearing preservation in adult patients following cochlear implantation.

Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, introduces its next generation Cochlear™ Osia® System with the ability to have an MRI at 3.0 T, designed to improve hearing outcomes for people with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness (SSD).

A recent clinical publication in the Journal of Clinical Medicine (JCM) highlighted early surgical experience with Envoy Medical®, Inc.’s (“Envoy Medical”) (NASDAQ: “COCH”) investigational Acclaim® fully implantable cochlear implant.

Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, receives U.S. Food and Drug Administration (FDA) approval for the Cochlear™ Nucleus® 8 Sound Processor.

Advanced Bionics is pleased to announce the appointment of Alistair Simpson as its new president, and Group Vice President (GVP) for cochlear implants on the Sonova Management Board, effective immediately.

Positive results from the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival and progression-free survival compared to placebo for patients with limited-stage small cell lung cancer who had not progressed following standard-of-care concurrent chemoradiotherapy.

MED-EL, a leader in implantable hearing solutions, celebrates together with everyone living with and benefiting from cochlear implants.